AIM ImmunoTech Inc.
No SEC Form 4 filings for $AIM in the last 30 days.
See all $AIM insider activity →AIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 31, 2026 through September 3, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a total of five exchange agreements (the “Exchange Agreements”) and, for each, a corresponding partitioned promissory note (togethe
AIM ImmunoTech (AIM) received a U.S. patent for Ampligen combined with Keytruda for cancer treatment, extending protection to 2039. The patent covers multiple cancers, with a focus on pancreatic cancer. AIM's stock rose 3.36% on Friday and 42.92% in pre-market trading.
AIM ImmunoTech reported Q2 2026 results, with net loss of about $3.8M, or $0.43/share, versus $2.8M, or $3.68/share, a year earlier. It said the final patient in its Phase 2 DURIPANC trial received Ampligen ahead of schedule. Primary endpoint analysis starts Dec 2026, topline results in Q1 2027. Cash was $9.9M.
Over the past 7 days, alphai's AI scored 2 news stories mentioning AIM (AIM ImmunoTech Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent AIM coverage spans corporate actions, technology and earnings.
The conversion dilutes existing shareholders but removes debt, likely supporting short‑term price stability.
The new patent strengthens AIM ImmunoTech's IP portfolio and could improve future licensing or partnership prospects.
The ahead-of-schedule dosing and updated clinical timeline are near-term catalysts for sentiment and positioning ahead of primary endpoint analysis.
This is a primary earnings-style disclosure via SEC filing, but the scraped text does not include the actual financial figures or guidance.
The filing signals a new, contract-driven manufacturing and development commitment that could affect near-term execution risk and future supply/cost structure.
alphai scores every news story that mentions AIM with an AI model for sentiment and relevance, and aggregates insider trades from AIM ImmunoTech Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 31, 2026 through September 3, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a total of five exchange agreements (the “Exchange Agreements”) and, for each, a corresponding partitioned promissory note (togethe
2 min readAIM ImmunoTech (AIM) received a U.S. patent for Ampligen combined with Keytruda for cancer treatment, extending protection to 2039. The patent covers multiple cancers, with a focus on pancreatic cancer. AIM's stock rose 3.36% on Friday and 42.92% in pre-market trading.
1 min readAIM ImmunoTech reported Q2 2026 results, with net loss of about $3.8M, or $0.43/share, versus $2.8M, or $3.68/share, a year earlier. It said the final patient in its Phase 2 DURIPANC trial received Ampligen ahead of schedule. Primary endpoint analysis starts Dec 2026, topline results in Q1 2027. Cash was $9.9M.
4 min readAIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer Completed Enrollment and Ampligen Do
2 min readAIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On July 31, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a proposal (the “Proposal Agreement”) with Sterling Pharma Solutions (the “Manufacturer”) that is related to the Master Service Agreement and a Quality Agreeme
7 min readAIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement As previously disclosed, AIM ImmunoTech Inc. (the “Company”) is a party to the Equity Distribution Agreement (the “Agreement”), dated April 1, 2025, as amended on April 10, 2026, with Maxim Group LLC (the “Sales Agent”), pu
2 min readAiM Medical Robotics appointed Andrew Aberdale as president and CFO, effective Tuesday, after serving as acting CFO since February. The U.S. company develops a portable robotic surgery system for image-guided procedures. AiM said the move will support clinical and commercial deployment, including its May partnership with Siemens Healthineers to integrate Magnetom MRI scanners. AiM last raised $8.1 million Series A in September.
2 min readAIM ImmunoTech said its Phase 2 pancreatic cancer trial of Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) after FOLFIRINOX reached final patient enrollment ahead of schedule. The company expects to complete dosing and assess the primary Clinical Benefit Rate endpoint in December 2026, while continuing Phase 3 planning and expanding regulatory and IP efforts.
4 min readThe US Treasury Department said at a New York industry event that some Wall Street “tax alpha” strategies may be abusive and it is evaluating tools to address them, without announcing new guidance. Strategies cited include 351 conversions, box-spread ETFs, ordinary-income offsets, and ETF switching to avoid dividends. AQR’s Delphi Plus Fund was highlighted; AQR fell 7% on Tuesday.
7 min readThe U.S. Treasury said it is evaluating whether certain “tax alpha” strategies and products may be “potentially abusive,” citing concerns about transactions such as 351 conversions, box-spread ETFs, ordinary-income offsets, and ETF structures that avoid dividend taxes. Officials sought industry input without announcing new rules. AQR’s Delphi Plus Fund had $6.6B (as of June 30) and ordinary losses equal to 28% of capital invested; Affiliated Managers Group fell 7%.
6 min read
